
News from curetoday.com
Top curetoday.com News

Science · United States(MedPage Today) -- The comeback story of belantamab mafodotin (Blenrep) hit a roadblock Thursday as the FDA's Oncologic Drugs Advisory Committee (ODAC) voted that the drug does not have a favorable benefit-risk profile in combination with either...See the Story
Myeloma Drug's Comeback Nixed by FDA Panel
72% Center coverage: 7 sources

United States · United StatesDoptelet and new oral sprinkle granules is approved for children one year and older with chronic immune thrombocytopenia, showing 28% durable platelet response in study.See the Story
FDA Approves Doptelet With Sprinkle Form for Pediatric Immune Thrombocytopenia
100% Right coverage: 1 sources